AIA
PVLA

Affinity Investment Advisors’s Palvella Therapeutics PVLA Stock Holding History

Affinity Investment Advisors’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-759
Closed -$308K – 195
2018
Q2 		$308K Hold
759
– – 0.04% 161
2018
Q1 		$414K Buy
+759
New +$470K 0.05% 119

Other funds holding PVLA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Affinity Investment Advisors's PVLA Position: Q3 2018 in Review

Affinity Investment Advisors sold out of Palvella Therapeutics (PVLA) in Q3 2018, closing a stake of 759 shares — an estimated $308K sold.

Affinity Investment Advisors first reported a position in PVLA in Q1 2018 and held it in 2 quarters. The position peaked at $414K in Q1 2018. 105 funds tracked by Wall St. Rank hold PVLA as of Q3 2018.

  • Affinity Investment Advisors reported no remaining Palvella Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Affinity Investment Advisors sold 759 Palvella Therapeutics shares in Q3 2018, an estimated $308K.
  • Affinity Investment Advisors first reported a position in Palvella Therapeutics in Q1 2018 and held it in 2 quarters.
  • Affinity Investment Advisors's Palvella Therapeutics position peaked at $414K in Q1 2018.
  • 105 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q3 2018.

Based on Affinity Investment Advisors's 13F filing for Q3 2018, filed 9 Nov 2018.